FA
BIIB icon

Fagan Associates’s Biogen BIIB Stock Holding History

Fagan Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,505
Closed -$652K – 96
2016
Q1 		$652K Buy
2,505
+110
+5% +$29.1K 0.43% 57
2015
Q4 		$734K Buy
2,395
+345
+17% +$99.1K 0.49% 53
2015
Q3 		$598K Buy
2,050
+140
+7% +$46.2K 0.44% 59
2015
Q2 		$772K Buy
1,910
+820
+75% +$329K 0.52% 56
2015
Q1 		$460K Buy
+1,090
New +$430K 0.34% 67

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fagan Associates's BIIB Position: Q2 2016 in Review

Fagan Associates sold out of Biogen (BIIB) in Q2 2016, closing a stake of 2,505 shares — an estimated $652K sold.

Fagan Associates first reported a position in BIIB in Q1 2015 and held it in 5 quarters. The position peaked at $772K in Q2 2015. 967 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

  • Fagan Associates reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
  • Fagan Associates sold 2,505 Biogen shares in Q2 2016, an estimated $652K.
  • Fagan Associates first reported a position in Biogen in Q1 2015 and held it in 5 quarters.
  • Fagan Associates's Biogen position peaked at $772K in Q2 2015.
  • 967 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Fagan Associates's 13F filing for Q2 2016, filed 5 Aug 2016.